Hebei Changshan Biochemical Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Hebei Changshan Biochemical Pharmaceutical's earnings have been declining at an average annual rate of -73%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 9.1% per year.
Key information
-73.0%
Earnings growth rate
-73.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -9.1% |
| Return on equity | -49.7% |
| Net Margin | -80.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hebei Changshan Biochemical Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,055 | -845 | 318 | 82 |
| 30 Jun 24 | 1,158 | -1,131 | 432 | 108 |
| 31 Mar 24 | 1,203 | -1,306 | 570 | 137 |
| 31 Dec 23 | 1,410 | -1,240 | 646 | 159 |
| 30 Sep 23 | 1,682 | -438 | 600 | 130 |
| 30 Jun 23 | 2,010 | -203 | 660 | 147 |
| 31 Mar 23 | 2,264 | -8 | 687 | 147 |
| 01 Jan 23 | 2,336 | 18 | 746 | 145 |
| 30 Sep 22 | 2,603 | 94 | 918 | 160 |
| 30 Jun 22 | 2,697 | 141 | 1,035 | 150 |
| 31 Mar 22 | 2,832 | 195 | 1,115 | 146 |
| 01 Jan 22 | 2,968 | 234 | 1,220 | 151 |
| 30 Sep 21 | 2,885 | 255 | 1,217 | 149 |
| 30 Jun 21 | 2,771 | 279 | 1,203 | 139 |
| 31 Mar 21 | 2,676 | 273 | 1,189 | 145 |
| 31 Dec 20 | 2,364 | 253 | 1,100 | 128 |
| 30 Sep 20 | 2,280 | 236 | 1,132 | 127 |
| 30 Jun 20 | 2,178 | 233 | 1,098 | 138 |
| 31 Mar 20 | 2,011 | 217 | 1,029 | 136 |
| 31 Dec 19 | 2,071 | 225 | 1,045 | 136 |
| 30 Sep 19 | 1,930 | 173 | 972 | 111 |
| 30 Jun 19 | 1,841 | 157 | 901 | 103 |
| 31 Mar 19 | 1,783 | 151 | 853 | 105 |
| 31 Dec 18 | 1,653 | 140 | 776 | 99 |
| 30 Sep 18 | 1,691 | 225 | 721 | 98 |
| 30 Jun 18 | 1,621 | 219 | 623 | 126 |
| 31 Mar 18 | 1,493 | 199 | 613 | 94 |
| 31 Dec 17 | 1,420 | 197 | 577 | 76 |
| 30 Sep 17 | 1,189 | 208 | 462 | 59 |
| 30 Jun 17 | 1,119 | 190 | 508 | 0 |
| 31 Mar 17 | 1,143 | 190 | 487 | 0 |
| 31 Dec 16 | 1,118 | 175 | 484 | 0 |
| 30 Sep 16 | 1,082 | 171 | 493 | 0 |
| 30 Jun 16 | 1,008 | 165 | 451 | 0 |
| 31 Mar 16 | 949 | 161 | 414 | 0 |
| 31 Dec 15 | 916 | 156 | 400 | 0 |
| 30 Sep 15 | 895 | 147 | 351 | 0 |
| 30 Jun 15 | 877 | 139 | 336 | 0 |
| 31 Mar 15 | 831 | 135 | 326 | 0 |
| 31 Dec 14 | 811 | 134 | 296 | 0 |
| 30 Sep 14 | 716 | 119 | 298 | 0 |
| 30 Jun 14 | 693 | 116 | 264 | 0 |
| 31 Mar 14 | 723 | 116 | 255 | 0 |
| 31 Dec 13 | 705 | 115 | 242 | 0 |
Quality Earnings: 300255 is currently unprofitable.
Growing Profit Margin: 300255 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300255 is unprofitable, and losses have increased over the past 5 years at a rate of 73% per year.
Accelerating Growth: Unable to compare 300255's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300255 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).
Return on Equity
High ROE: 300255 has a negative Return on Equity (-49.72%), as it is currently unprofitable.